随着肿瘤免疫治疗领域迅速发展,越来越多关于PD-1和PD-L1抑制剂的研究因良好的治疗效果与安全性获批上市。目前,国内已上市的单抗类免疫检查点抑制剂有17款,其中PD-1抑制剂共有11款、PD-L1抑制剂5款。这么多款免…
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)为代表的免疫疗法通过激活患者自身 T 淋巴细胞的抗肿瘤免疫功能,发挥杀灭肿瘤细胞的作用,在临床上已被广泛使用。 ICIs 作为针对细胞毒性 T 淋巴细胞相关…
PD-1/PD-L1 inhibitorsCompounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed Formula (I)AKTOUDIANAKIS EvangelosCHO AesopDU Zhimin...
PD-1-PD-L1 Inhibitors on signaling pathway are available at Adooq Bioscience. Check PD-1-PD-L1 pathway , inhibitors reviews and assay information.
PD-1 And PD-L1 Inhibitors Market Analysis The PD-1 And PD-L1 Inhibitors Market size is estimated at USD 63.73 billion in 2025, and is expected to reach USD 145.56 billion by 2030, at a CAGR of 17.96% during the forecast period (2025-2030). ...
为解决 PD-1/PD-L1 抑制剂仅对 MSI-H CRC 有效、MSS 患者应答差等问题,研究人员开展肠道菌群联合该抑制剂治疗 CRC 的研究,纳入 8 项动物研究和 5 项临床研究,发现联合疗法有前景,为临床提供新方向。 结直肠癌(CRC)是全球范围内发病率和死亡率均居高不下的恶性肿瘤。目前,手术切除仍是主要治疗手段,但免疫...
We summarize the ongoing international and domestic clinical trials using PD-1 and PD-L1 inhibitors to treat lung cancer. This information can help researchers better understand the active and approved clinical trials in China, as well as the ongoing research regarding PD-1 and PD-L1 inhibitors....
非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识 01 引言 近年来,以程序性死亡受体1(programmed death-1, PD-1)/PD配体1(PD ligand 1, PD-L1)免疫检查点抑制剂为主的免疫治疗在晚期肺癌中取得了突破性的进展,改变了该领域的治疗...
近年来,以程序性死亡受体1(programmed death-1, PD-1)/PD配体1(PD ligand 1, PD-L1)免疫检查点抑制剂为主的免疫治疗在晚期肺癌中取得了突破性的进展,改变了该领域的治疗格局,为患者带来了更多生存获益。虽然对于免疫治疗适宜人群筛选和疗效预测的生物标志物越来越多,但PD-L1仍是目前应用最为广泛的指标。免疫组...
其潜在机制可能与 COPD 中 PD-1/PD-L1 通路的异常表达有关 —— 轻度 COPD 患者的 PD-L1 升高可能诱导了免疫细胞耗竭表型,反而使肿瘤对 PD-(L) 1 阻断更敏感。这一发现不仅拓展了抗 PD-(L) 1 治疗的适用人群,也为临床筛选优势患者提供了新视角:未来或可通过肺功能检查(尤其是 spirometry)识别潜在获益...